Discovery of ZJC-11 as a Novel Selective CDK7 Inhibitor for Treating Triple-Negative Breast Cancer by Inducing Cell Senescence
Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 18364-18385
DOI: 10.1021/acs.jmedchem.6c00771 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 27.07.2026. Verfasst von Bo Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing400016, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Cellular Senescence, Cyclin-Dependent Kinases, Protein Kinase Inhibitors. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Chongqing Medical University, Natural Science Foundation of Chongqing Municipality.
Abstract (Originalsprache)
The development of cyclin-dependent kinase 7 (CDK7) inhibitors represents a promising therapeutic strategy for triple-negative breast cancer (TNBC). Herein, we designed and synthesized 21 novel CDK7-targeted small molecules and identified ZJC-11 as a potent lead candidate. ZJC-11 demonstrated significant antiproliferative activity against TNBC both in vitro and in vivo, with reduced toxicity compared to the reported CDK7 inhibitor THZ1. Molecular docking, Kinact/KI tests, kinase selectivity profiling, and pharmacokinetic studies confirmed that ZJC-11 selectively and covalently targets CDK7 with favorable pharmacokinetic properties. RNA sequencing and functional analyses revealed that ZJC-11 not only suppresses transcription and G2/M cell cycle checkpoint pathways but also induces DNA damage-driven cellular senescence, ultimately leading to TNBC cell death. Moreover, ZJC-11 not only exhibited a synergistic anti-TNBC effect when combined with doxorubicin but also alleviated doxorubicin-induced cardiotoxicity, a clinically significant adverse effect, highlighting its promise as a therapeutic candidate for TNBC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing400016, China.
- Chongqing Key Laboratory of Drug Metabolism, Chongqing Medical University, Chongqing400016, China.
- Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Chongqing400016, China.
- State Key Laboratory of Neurology and Oncology Drug Development, Nanjing210008, China.
- Department of Medicinal Chemistry, College of Pharmacy, Chongqing Medical University, Chongqing400016, China.
- Chongqing Key Laboratory of Quality Control and Safety Evaluation of APIs, Chongqing Medical University, Chongqing400016, China.
ORCID-Profile: Zongjie Gan, Weiying Zhou
Förderung
- National Natural Science Foundation of China
- Chongqing Medical University
- Natural Science Foundation of Chongqing Municipality
- Chongqing Municipal Education Commission
- State Key Laboratory of Neurology and Oncology Drug Development
Zitieren
APA
Chen, B., Wu, L., Zhang, L., Liu, M., Zheng, J., Wang, G., Wu, Y., Chen, X., Yin, M., Hu, Q., Huang, G., Wang, B., Tian, X., Shen, Z., Gan, Z., & Zhou, W. (2026). Discovery of ZJC-11 as a Novel Selective CDK7 Inhibitor for Treating Triple-Negative Breast Cancer by Inducing Cell Senescence. Journal of Medicinal Chemistry, 69(15), 18364-18385. https://doi.org/10.1021/acs.jmedchem.6c00771
Vancouver
Chen B, Wu L, Zhang L, Liu M, Zheng J, Wang G, et al. Discovery of ZJC-11 as a Novel Selective CDK7 Inhibitor for Treating Triple-Negative Breast Cancer by Inducing Cell Senescence. Journal of Medicinal Chemistry. 2026;69(15):18364-18385. doi:10.1021/acs.jmedchem.6c00771
BibTeX
@article{Chen2026,
author = {Chen, Bo and Wu, Lihong and Zhang, Limei and Liu, Mingpu and Zheng, Jiecheng and Wang, Gang and Wu, Yuanli and Chen, Xiaojiao and Yin, Manjialan and Hu, Qinghua and Huang, Guangxu and Wang, Bowen and Tian, Xinhong and Shen, Zhengze and Gan, Zongjie and Zhou, Weiying},
title = {Discovery of ZJC-11 as a Novel Selective CDK7 Inhibitor for Treating Triple-Negative Breast Cancer by Inducing Cell Senescence},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {15},
pages = {18364--18385},
doi = {10.1021/acs.jmedchem.6c00771}
}
EUVIMED